Jun 6, 2022 | Press Releases
Data from trials underscore ImmunityBio’s vision of activating NK cells and T cells to advance care in difficult-to-treat cancers Bladder Cancer: 71% of BCG-unresponsive NMIBC patients who had failed on previous therapies showed a complete response with a median...
May 23, 2022 | Press Releases
Results for this FDA-designated Breakthrough Therapy exceed historical complete response rates and duration of response of current approved therapies for this indication CULVER CITY, Calif., May 23, 2022 –ImmunityBio, Inc. (NASDAQ: IBRX), a clinical-stage...
Apr 28, 2022 | Press Releases
Data from ImmunityBio’s QUILT 3.032 BCG-unresponsive non-muscle invasive bladder cancer trial will be presented by principal investigator in an oral presentation Poster presentation of QUILT 88 pancreatic data CULVER CITY, Calif., April 28, 2022 – ImmunityBio, Inc....
Apr 25, 2022 | Press Releases
Novel combination therapy of Anktiva, an IL-15 superagonist, and Keytruda targeted at patients with lung cancer who have failed checkpoint inhibitor therapy The study currently includes nearly 200 U.S. sites and will involve 478 patients when fully enrolled Nearly...
Apr 1, 2022 | Press Releases
CULVER CITY, Calif., April 1, 2022 – ImmunityBio, Inc. (NASDAQ: IBRX), a clinical-stage immunotherapy company, today announced that it has achieved a major milestone with over 80 subjects in the QUILT-3.032 study completing at least 12 months of follow-up as of...
Mar 2, 2022 | Press Releases
Natural killer (NK) cells play a critical role in the innate immune system’s ability to combat cancer, but the key to long-term treatment effectiveness is ensuring their persistence A Washington University School of Medicine study shows that increasing NK cell...
